Deborah L. White, Jerald Radich, Simona Soverini, Verity A Saunders, Amity K. Frede, Phuong Dang, Daniela Cilloni, Peter Lin, Lidia Mongay, Richard Woodman, Paul Manley, Cassandra Slader, Dong Wook Kim, Fabrizio Pane, Giovanni Martinelli, Giuseppe Saglio, Timothy P. Hughes. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. haematol [Internet]. 2012Jun.4 [cited 2024Nov.22];97(6):907-14. Available from: https://haematologica.org/article/view/6331